主要文件

查看所有文档

D1900000

地高辛

Name: 地高辛
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

别名:

异羟基洋地黄毒苷

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₄₁H₆₄O₁₄

化学文摘社编号:

20830-75-5

分子量:

780.94

UNSPSC Code:

41116107

NACRES:

NA.24

PubChem Substance ID:

329798713

MDL number:

MFCD00003674

Beilstein/REAXYS Number:

77011

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

pharmaceutical primary standard

API family

digoxin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]2[C@@H](O)C[C@@H](O[C@@H]2C)O[C@H]3[C@@H](O)C[C@@H](O[C@@H]3C)O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]7(C)[C@H](CC[C@]67O)C8=CC(=O)OC8)C4

InChI

1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1

InChI key

LTMHDMANZUZIPE-PUGKRICDSA-N

Gene Information

human ... ATP1A1(476), ATP1A2(477), ATP1A3(478), ATP1A4(480), ATP1B1(481), ATP1B2(482), ATP1B3(483), FXYD2(486)

说明

General description

本品按现行药典规定交付。所有为支持本产品而提供的信息，包括SDS和任何产品信息单均由药典颁发机构制定并发布。如需进一步信息和支持，请访问现行药典网站。

Application

地高辛EP 参考标准品设计用于欧洲药典规定的实验室测试。

Biochem/physiol Actions

一种强心苷，P-糖蛋白 (Pgp) 的底物。

一种强心苷，P-糖蛋白的底物，上调 Pgp 表达和下调 SXR（固醇类异生物受体）。

Packaging

本品按照现行药典要求提供。有关当前单位数量，请见EDQM 参考目录。

Other Notes

可能适用相应的销售限制。

Still not finding the right product?

Explore all of our products under 地高辛

pictograms

GHS06,GHS08

signalword

Danger

hcodes

H300,H331,H373

pcodes

P260 - P264 - P271 - P301 + P310 - P304 + P340 + P311 - P314

Hazard Classifications

Acute Tox. 2 Oral - Acute Tox. 3 Inhalation - STOT RE 2

存储类别

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

法规信息

危险化学品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Application of permeability-limited physiologically-based pharmacokinetic models: part I-digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux.

Sibylle Neuhoff et al.

Journal of pharmaceutical sciences, 102(9), 3145-3160 (2013-05-25)

A prerequisite for the prediction of the magnitude of P-glycoprotein (P-gp)-mediated drug-drug interactions between digoxin and P-gp inhibitors (e.g. verapamil and its metabolite norverapamil) or P-gp inducers (e.g. rifampicin) is a predictive pharmacokinetic model for digoxin itself. Thus, relevant in

Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study).

Ryozo Nagai et al.

Circulation journal : official journal of the Japanese Circulation Society, 77(4), 908-916 (2013-03-19)

A rapid heart rate (HR) during atrial fibrillation (AF) and atrial flutter (AFL) in left ventricular (LV) dysfunction often impairs cardiac performance. The J-Land study was conducted to compare the efficacy and safety of landiolol, an ultra-short-acting β-blocker, with those

VEGF secreted by hypoxic Müller cells induces MMP-2 expression and activity in endothelial cells to promote retinal neovascularization in proliferative diabetic retinopathy.

Murilo Rodrigues et al.

Diabetes, 62(11), 3863-3873 (2013-07-26)

In proliferative diabetic retinopathy (PDR), retinal ischemia promotes neovascularization (NV), which can lead to profound vision loss in diabetic patients. Treatment for PDR, panretinal photocoagulation, is inherently destructive and has significant visual consequences. Therapies targeting vascular endothelial growth factor (VEGF)

查看所有相关文献

全球贸易项目编号

货号	GTIN
D1900000	04061833792919